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ABSTRACT
MicroRNAs (miRNAs) are small endogenous
non-coding RNAs that regulate post-transcriptional
gene expression and are important in many bio-
logical processes. Disease-associated miRNAs
have been shown to become potential targets for
therapeutic intervention. Functions of miRNAs can
be inhibited by using antisense oligonucleotides,
called anti-miRs, complimentary to the miRNA se-
quences. Here, we show that systemic delivery of a
chemically stabilized anti-miR-122 complexed with
interfering nanoparticles (iNOPs) effectively silences
the liver-expressed miR-122 in mice. Intravenous
administration of 2mgkg
 1 chemically modified
anti-miR-122 complexed with iNOP-7 resulted in
83.2±3.2% specific silencing of miR-122, which
was accompanied by regulating gene expression
in liver and lowering of plasma cholesterol. The
specific silencing of miR-122 was long lasting and
did not induce an immune response. Our results
demonstrate that iNOPs can successfully deliver
anti-miR to specifically target and silence miRNA
in clinically acceptable and therapeutically afford-
able doses.
INTRODUCTION
MicroRNAs (miRNAs) are small endogenous non-coding
RNAs that post-transcriptionally regulate gene expres-
sion by binding with imperfect complementarity in
30-untranslated regions (30-UTR) of their target mRNAs
(1–4). miRNAs have been shown to play an important
role in development, and cell growth and differentiation
(5,6). Recent studies have highlighted the role of miRNAs
in various disease states and in regulating host–pathogen
interactions (7). For example, mRNAs have been
implicated in cardiovascular disease (8), inﬂammation
(9), viral infections (10–13) and cancers (14,15). Hence,
disease-associated miRNAs could become potential
targets for therapeutic intervention (7).
MicroRNA-122 (miR-122) is a liver-speciﬁc miRNA,
with suggested roles in cholesterol, fatty acid and lipid me-
tabolism (16–18). miR-122 interacts with hepatitis C virus
genome facilitating viral replication in host cell (10,19,20).
In vivo silencing of miR-122 has been achieved by systemic
administration of antagomirs or modiﬁed antisense oligo-
nucleotides in mice or non-human primates (16–18,21).
These studies were very encouraging in providing proof
of the concept for silencing miRNA by its anti-miR
sequences in vivo. Recently, therapeutic silencing of
miR-122 in primates with chronic hepatitis C virus infec-
tion has been reported by using locked nucleic acid (LNA)
modiﬁed oligonucleotide (SPC3649) complimentary to
miR-122 (22). Remarkably, SPC3649 treatment caused
long-lasting suppression of HCV viremia in primates with
no apparent evidence of side effects or viral resistance
indicating that the anti-miR therapeutic strategy could
lead to the development of new drugs for viral infections.
We recently reported successful silencing of apoB mRNA
by iNOP-7 after systemic administration of 1mgkg
 1
siRNA in mice (23). iNOP-7 is a new nanomaterial for
systemic delivery of RNAi developed by our laboratory,
which is a lysine-containing nanoparticle with the surface
functional groups modiﬁed with lipid chains (23,24). A
clear correlation between siRNA localization, cellular
uptake and RNAi activity was observed when siRNA
was delivered into cells using siRNA-TAT47–57-peptide,
siRNA-TAT47–57-derived oligocarbamate conjugates or
nanoparticles (25). For successful RNAi, the localization
of siRNA was distinctly cytoplasmic suggesting that
siRNA is targeted to these regions for interactions with
RISC to induce RNAi (25). Recent advances in under-
standing the rules for chemically modifying siRNA
sequences without compromising their gene-silencing efﬁ-
ciency [(26–28), reviewed in (4)] have allowed the design
and synthesis of therapeutically effective siRNA molecules
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(32)]. We reasoned that a chemically stabilized anti-miR
could be assembled with iNOP-7 to target miRNA se-
quences and inhibit their functions in vivo. To enhance
the stability of anti-miR molecules, we chemically
stabilized the oligonucleotides according to modiﬁcation
rules established in our previous studies [(27,28), reviewed
in (4)]. In this study, we tested this concept and determined
the silencing efﬁciency of miR-122 using iNOP-7 in mice.
MATERIALS AND METHODS
Oligonucleotides
RNAs were purchased from Dharmacon (Lafayette, CO,
USA) and consisted of 23-24 nucleotides length with
modiﬁcations as speciﬁed: chemically modiﬁed anti-miR-
122 (CM): 50-AC
FAAAC
FAC
FC
FAUUGUCACACUCC
A-30; chemically modiﬁed mismatch anti-miR-122 (MM):
50-UCAC
FAAC
FCUCC
FUAGAAAGAGUAGA-30. The
superscript letter F represents 20-O-F modiﬁed nucleo-
tides. Chemical modiﬁcations were designed based on
our previously published rules established in our labora-
tory [(27,28), reviewed in (4)]. The complexes were
prepared by mixing CM or MM anti-miR with iNOP-7
at a ratio of 1:10 (w/w) in HEPES saline or Opti-MEM
culture medium (Invitrogen, Carlsbad, CA, USA) and
incubating at room temperature for 20min (see below).
In vitro silencing miR-122
Huh-7 cells (kindly provided by John Taylor, Fox Chase
Cancer Center) were maintained at 37 C with 5% CO2 in
DMEM with High Glucose culture medium (Invitrogen,
Carlsbad, CA, USA) supplemented with 10% fetal bovine
serum, 100Uml
 1 penicillin and 100mgml
 1 strepto-
mycin. Cells were regularly passaged and plated in
6-well culture plates for 16h before transfection at 70%
conﬂuency. The anti-miRs were transfected in Opti-MEM
serum free culture medium for 4h at 37 C, and then
changed to normal medium with 10% FBS. Efﬁciency of
silencing was determined by northern blotting as described
below.
Dual luciferase assay
The miR-122 luciferase constructs were engineered by in-
serting the full 23-bp sequence complementary to the
mature miR-122 into the 30-UTR of pGL3-Control
(Promega, Madison WI, USA). Huh-7 cells were seeded
in 24-well culture plates and transfected with 0.1mg
miR-122 pGL3-control plasmid and 0.015mg pRL-TK
plasmid (Promega, Madison WI, USA) for normalization
using iNOP-7. After 4h of transfection, cells were treated
with complete media. Cells were lysed 48h later, unless
otherwise indicated, and luciferase activity was measured
using the Dual-Luciferase Reporter Assay System
(Promega, Madison WI, USA). These quantitative
assays were conducted in multiple replicates for each
concentration.
In vivo silencing miR-122
All animal procedures were approved by the Institutional
Animal Care and Use Committee (University of
Massachusetts Medical School). Six- to eight-week-old
male C57BL/6 mice (Charles River Laboratories,
Wilmington, MA, USA) were maintained under a 12h
dark cycle in a pathogen-free animal facility. Mice were
administrated with either phosphate buffered saline (PBS)
pH 7.4 or iNOP-7 complexes (as indicated) at 2mgkg
 1
body weight in 0.2ml per injection as bolus injection via
the lateral tail vein at 0, 12 and 36h. Measurements of
miRNA or mRNA levels in tissues were performed 24h
after the last injection unless indicated otherwise. Liver
and plasma were collected and stored in  80 C until
analysis. The in vivo silencing experiments were repeated
at least twice and multiple samples were collected from
tissues for quantitative analysis.
Northern blotting
RNA from cell culture or mouse livers was homogenized
in TRIZOL (Invitrogen, Carlsbad, CA, USA) and isolated
according to the manufacturer’s instructions. Total RNA
was separated on a 14% acrylamide/20% formamide/8M
urea gel, then electroblotted onto Hybond-XL nylon
membrane (GE Healthcare, Piscataway, NJ, USA). The
probe with g-
32P-labeled oligonucleotides for miRNA or
rRNA was hybridized to the membrane at 42 C. The blots
were visualized by scanning in a FLA-5000 scanner
(Fujiﬁlm, Stamford, CT, USA).
Quantitative RT/PCR
To determine regulations of mRNA levels in mouse tissues
after anti-miR treatment, total RNA was extracted with
TRIZOL (Invitrogen, Carlsbad, CA, USA) and treated
with TURBO DNA-free kit (Applied Biosystems, Foster
City, CA, USA) before quantiﬁcation. At least two liver
regions were used to extract total RNA from individual
animals in each group of three animals. In preparation for
quantitative PCR, total RNA (400ng) was reverse
transcribed by using SuperScript II (Invitrogen, Carlsbad,
CA, USA) and random primers according to the manufac-
turer’s protocol. The expression of mRNA was measured
using ABsolute QPCR SYBR green mix (ThermoFisher
Scientiﬁc, Epsom, Surrey, UK) normalized to GAPDH ac-
cording to the manufacturer’s instructions. Quantitative
PCR was performed by using a Chromo4 Real-Time PCR
Detection System (BioRad, Hercules, CA, USA). We used
the following primers: ACACB forward: GGGCTCCCTG
GATGACAAC, reverse: TTCCGGGAGGAGTTCTGG
A; Acas2 forward: GTGGCCATATGCTGACCCCTCT
CC, reverse: GGCAGCCATCTCCGGTCACATAGT;
AldoA forward: CAGGAAAGCAACTGCCACCGGCA
C, reverse: GGATTCACACGGTCGTCTGCAGTC;
ApoB forward: TTCCAGCCATGGGCAACTTTACCT,
reverse: TACTGCAGGGCGTCAGTGACAAAT; FASN
forward:ACGAGTGAGTGTACGGGAGG,reverse:GA
CCAGGGTGTCTCCAAGTC; GAPDH forward: ATCA
AGAAGGTGGTGAAGCAGGCA, reverse: TGGAAG
AGTGGGAGTTGCTGTTGA; GYS1 forward: CGGCT
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ATGTAAATG; HMGCR forward: TCTGGCAGTCAG
TGGGAACTATT, reverse: CCTCGTCCTTCGATCCA
ATTT; P4HA1 forward: CTGTTCTGCCGCTACCAT
GA, reverse: CCCACTCGTCCTCCTGCTT; SCD1
forward: TTCCGCCACTCGCCTACA, reverse: CTTTC
CCAGTGCTGAGATCGA; SLC7A1 forward: GCAAC
TTGGACCAGTGCAAA, reverse: ACCCGTCAACCG
CTGTCA.
Measurement of total cholesterol levels in plasma
Plasma cholesterol was measured by Cholesterol E kit ac-
cording to the manufacturer’s instructions (Wako,
Richmond, VA, USA). Three animals in each group and
two aliquots of plasma samples were used for measure-
ment of cholesterol.
In vivo interferon induction
To assess for any non-speciﬁc immune response to injected
iNOP-containing anti-miR, mouse liver tissue RNA was
analyzed for expression of the IFN-inducible genes by
quantitative RT-PCR. At least two liver regions were
used to extract total RNA from individual animals in
each group of three animals.
Statistical analysis
Results are given as means±SD. Statistical analyses were
preformed with Student’s t-test, and the null hypothesis
was rejected at the 0.05 levels. We also performed one-way
ANOVA analysis and the results showed that chemically
modiﬁed group was signiﬁcantly different from other two
groups (P<0.5).
RESULTS AND DISCUSSION
We ﬁrst evaluated the silencing potency of iNOP-7 con-
taining chemically modiﬁed anti-miR-122 in Huh-7 cells.
We transfected these cells by iNOP-7-containing
anti-miR-122 and analyzed the miR-122 by northern
blotting (Figure 1A). iNOP-7 efﬁciently delivered
anti-miR-122 into the cells and speciﬁcally silenced
miR-122 in a dose-dependent manner. The endogenous
miR-122 was slightly reduced by 10pM of anti-miR-122
compared with nontransfected control and  90% of
miR-122 was silenced at 1nM, which is at least 50 times
lower than 20-OMe and/or LNA modiﬁed anti-miR inhibi-
tors transfected by Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) (33). These results suggest that
iNOP-7 can efﬁciently deliver our chemically modiﬁed
anti-miR to cytoplasm and the released anti-miR results
in lowering the miR-122 levels in cell (17). To determine
the speciﬁcity of our anti-miR delivery by iNOP, we
analyzed miR-22. Since miR-22 is highly expressed both
in Huh-7 cell line and mouse liver tissue, therefore,
miR-22 quantitation should serve as a control for the
speciﬁcity of anti-miR-122. Our results showed that the
expression level of miR-22 was unaffected by the transfec-
tion, indicating that the anti-miR silencing was miRNA
speciﬁc (Figure 1A and B).
To evaluate the speciﬁc anti-miRNA effectiveness, we
incorporated the perfectly complementary miR-122
binding sites into the 30-UTR of a luciferase sensor
plasmid as previously reported (34–36). When the
reporter was transfected into Huh-7 cells, the endogenous-
ly expressed miR-122 strongly repressed the luciferase
sensor expression by binding with perfect complementar-
ity and causing cleavage of the mRNA. Introduction of
anti-miR-122 by iNOP-7 prevented this miR-122-
mediated repression, resulting in increased luciferase ex-
pression (Figure 2). The results are inversely consistent
with the silencing effect of endogenous miR-122 by
iNOP-7 containing anti-miR-122 detected by northern
blotting in Figure 1.
We next determined the ability of iNOP-7 to deliver
anti-miR-122 to its target and silence miR-122 in vivo.I n
our previous experiments, we observed efﬁcient silencing
of ApoB as reported by Soutschek et al. (30) when we
injected mice with 80mgkg
 1 chemically modiﬁed
siRNA conjugated with cholesterol (data not shown).
Since 80mgkg
 1 doses of RNA are not clinically
feasible, our goal in this study was to test the ability of
iNOP-7 to inhibit miRNA functions at clinically accept-
able doses. Therefore, we did not pursue in vivo experi-
ments using RNA without the iNOP-7 assembly. Mice
were injected via tail vein with iNOP-7 complexed to
either chemically modiﬁed anti-miR-122 or its mismatch
Figure 1. Speciﬁc silencing of miR-122 in a dose-dependent manner by
iNOP-7 in vitro.( A) Huh-7 cells were transfected by iNOP-7 containing
anti-miR-122 at varying concentrations as indicated for 4h. Total RNA
was isolated from cells 24h after transfection and separated on 14%
polyacrylamide gels. Membrane was probed for miR-122 and miR-22,
respectively. 5S rRNA is shown as a loading control. (B) Quantiﬁcation
of reduced miR-122 levels in Huh-7 cells after transfected with iNOP-7
containing anti-miR-122. Northern blots of miR-122 and miR-22
(panel A) were analyzed by densitometry and normalized to 5S rRNA.
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were analyzed. miR-122 was signiﬁcantly lower in liver
tissue from mice treated with 2mg kg
 1 iNOP-7 contain-
ing chemically modiﬁed anti-miR-122 (83.2±6.4%, n=3
animals) than in livers from control mice (Figure 3). The
effects of anti-miR-122 were found to be speciﬁc because
mice injected with iNOP-7 containing mismatched
anti-miR-122 has no effect on miR-122. Furthermore,
the expression of miR-22 was unaffected in mice treated
with anti-miR-122 and its mismatch, suggesting that
silencing was miRNA speciﬁc.
We also tested the duration of silencing that could be
achieved after the injection of iNOP-7 containing chem-
ically modiﬁed anti-miR-122. Mice were injected with
2mg kg
 1 of iNOP-7 containing chemically modiﬁed
anti-miR-122 via tail vein, isolating liver tissues at
various times after injection, and analyzing liver for
miR-122 levels. At day 1, miR-122 level was signiﬁcantly
decreased (over 80% compared to PBS control mice), and
the effect lasted at least for 9 days, indicating that
silencing of miRNA by iNOP-7 containing chemically
modiﬁed anti-miR-122 is long lasting effects (Figure S1).
MicroRNA can regulate the mRNA levels of their
targets in 30-UTR (37,38) and pharmacological silencing
miRNAs using iNOP-7 containing chemically modiﬁed
anti-miR-122 might therefore lead to the regulation of
many mRNAs. To demonstrate the efﬁcacy of the
miRNA inhibition in vivo, the levels of a set of miR-122
target mRNAs identiﬁed previously (16,17) were
evaluated in quantitative RT-PCR (Figure 4). Four of
ten target mRNAs were increased in the anti-miR-122
treated mice, among which SLC7A1 mRNA was most
sensitive to miR-122 inhibition (fold increase 5.7±0.7)
(Figure 4A). The other six mRNAs were down-regulated
after the inhibition of miR-122 and SCD1 was decreased
to 4.3±1.7% of control after the inhibition (Figure 4B).
No target mRNA changes were observed in mice treated
with mismatched anti-miR-122, demonstrating speciﬁc in-
hibition of miR-122 activity in liver.
To investigate the physiological effects of miR-122
silencing on cholesterol metabolism, we measured total
plasma cholesterol levels in mice 24h after the last injec-
tion. Chemically modiﬁed anti-miR-122 mediated regula-
tion of gene expression in liver caused the reduction of
total cholesterol in plasma (26.3±12.5%) as shown in
Figure 4C. Cholesterol levels were unchanged in mice
receiving control treatments or treated with iNOP-7 con-
taining chemically modiﬁed, mismatched anti-miR-122.
This result demonstrates that iNOP-7-mediated targeting
of miR-122 could provide a clinically signiﬁcant new
approach to reducing cholesterol levels in patients with
hypercholesterolemia.
To address the concern of eliciting a non-speciﬁc
immune response by injecting animals with iNOP-7 con-
taining chemically modiﬁed anti-miR-122, liver tissue
RNA was assessed by quantitative PCR for the induction
of the interferon inducible genes interferon-induced
protein with tetratricopeptide repeats 1 (IFIT1), signal
transducers and activators of transcription 1 (STAT1)
and 20,50-oligoadenylate synthetase 1 (OAS1). Our
results showed that injecting mice with iNOP-7 containing
either chemically modiﬁed or mismatched anti-miR-122
did not alter the expression of these genes in the liver,
suggesting iNOP-7 treatment did not induce an immune
response in mice (Figure S2). Anti-miR-122 was well
Figure 3. Speciﬁc silencing of miR-122 in mice treated with iNOP-7
assembled with chemically modiﬁed anti-miR-122. (A) Mice were
intravenously injected with 2mgkg
 1 of iNOP-7 containing chemically
modiﬁed anti-miR-122, mismatched chemically modiﬁed anti-miR-122,
or PBS at 0, 12 and 36h. Tissues were harvested at 24h after the last
injection to measure miRNA or mRNA levels. Total RNA was isolated
from mouse liver 24h after last injection. Samples were separated
in 14% polyacrylamide gel and membrane was probed for miR-122,
miR-22 and 5S rRNA. 5S rRNA is shown as a loading control.
(B) Quantiﬁcation of reduced miR-122 levels in mice after treatment
with iNOP-7 containing anti-miR-122. Northern blots of miR-122
and miR-22 (A) were analyzed by densitometry after normalized
to 5S rRNA. Data are expressed as percent of control (two or three
animals).
Figure 2. Inhibition of miR-122 by iNOP-7 in vitro determined by dual
luciferase assays. Huh-7 cells were transfected with miR-122 luciferase
construct containing sequence complementary to the mature miR-122
into the 30-UTR and varying amounts of anti-miR oligonucleotides
using iNOP-7 for 4h. Cells were lysed 48h later, and luciferase
activities were measured using the Dual-Luciferase Reporter Assay
System as described previously (39,40). FL and RL represent ﬁreﬂy
luciferase and renilla luciferase, respectively.
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 1 of chemically
modiﬁed anti-miR-122 complexed with iNOP-7 on three
consecutive days; no alterations in overall health, body
weight and food intake were detected. Together, these
data indicate that iNOP-7 containing chemically
modiﬁed anti-miR-122 participates in regulation of the
cholesterol biosynthetic pathway and that silencing of a
miRNA can be achieved without apparent toxicities.
Taken together, our results show that the newly
designed nanoparticles can be used to deliver both
duplex siRNA as we reported previously (23) and
single-stranded anti-miR oligonucleotides to silence
disease-related endogenous genes or miRNA in clinically
acceptable and therapeutically affordable doses. When we
injected iNOP-7 containing chemically modiﬁed anti-miR
into animals, miRNA was speciﬁcally silenced and the
expression of target genes were subsequently altered in
liver, total plasma cholesterol was lowered. In addition,
iNOP-7 treatment was non-toxic and did not induce an
immune response. An important beneﬁt of employing
anti-miR oligonucleotides at low doses as presented here
is that these strategies would avoid non-speciﬁc effects
generated by the presence of excess anti-miR during puri-
ﬁcation and analysis procedures. Furthermore, iNOP-7
can be modiﬁed to target speciﬁc tissues and to
modulate pharmacological properties to develop tissue-
speciﬁc RNAi-based therapies. Although additional
studies will be needed to optimize the dosing regimen
and to assess the biodistribution and safety after long-
term treatment, our ﬁndings highlight the utility of
nanoparticles to deliver chemically modiﬁed anti-miR to
liver tissues to silence endogenous miRNA in mice at
clinical feasible doses.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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Figure 4. Regulations of gene expression by anti-miR-122-iNOP-7 treatment in mice. Mice were intravenously injected with 2mg kg
 1 of iNOP-7
containing chemically modiﬁed anti-miR-122, mismatched chemically modiﬁed anti-miR-122, or PBS at 0, 12 and 36h. Tissues were harvested at 24h
after the last injection to measure miRNA or mRNA levels. Total RNA was isolated from mouse liver 24h after last injection. mRNA levels were
up-regulated (A) or down-regulated (B) in liver 24h after last injection. Values represent the mean±SD of tissue samples for two liver regions (three
animals). Data are expressed as percent of PBS treated mice. AldoA, aldolase 1, A isoform; GYS1, glycogen synthase 1; P4HA1, procollagen-proline,
2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha 1 polypeptide; SLC7A1, solute carrier family 7 (cationic amino acid transporter, y+
system), member 1; ACACB, acetyl-coenzyme A carboxylase beta; Acas2, acetyl-coenzyme A synthetase 2; ApoB, apolipoprotein B; FASN, fatty acid
synthase; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; SCD1, stearoyl-coenzyme A desaturase 1. (C) Total cholesterol in plasma
after anti-miR-122 treatment of mice. Mice were injected with 2mgkg
 1 of iNOP-7 containing chemically modiﬁed anti-miR-122, mismatched
chemically modiﬁed anti-miR-122 and PBS on three consecutive days. Plasma was collected at 24h after last injection and total cholesterol was
measured by Cholesterol E kit from Wako (n=3 animals). *P<0.05.
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